Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs S&P Global Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $280 (market cap $39.89B), while S&P Global Inc trades at $436.13 (market cap $127.43B). The key difference: S&P Global Inc is far larger — about 3.2× Alnylam Pharmaceuticals, Inc.'s market cap, and S&P Global Inc pays a 0.9% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | SPGI | |
|---|---|---|
Market Cap | $39.89B | $127.43B |
Sector | Health | Financials |
52-Week High | $491.22 | $534.79 |
52-Week Low | $278.09 | $370.42 |
Enterprise Value | $38.15B | $139.39B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
S&P Global (SPGI) trades at $430.50, down 0.57% today, with strong fundamentals including 30.36% net income margin and consistent earnings beats. The technical outlook is bullish with support at $426 and resistance at $436. Recent corporate actions include the spin-off of Mobility Global and upcoming Q2 2026 earnings on July 28, 2026.
Outlook remains positive with 85.7% analyst buy ratings and a $531.56 consensus price target implying 23% upside. Risks include interest rate sensitivity and integration of new operating models. Revenue growth and margin expansion support long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
